NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma

19th September 2018 Uncategorised 0

The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

More: NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
Source: News